BioSpace News Archive

The 12-month data showed that 50 mg of zuranolone was well-tolerated among adults with MDD.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

The FDA’s decision is based on positive results from two Phase III trials, the PROTECT and CONSTANT, on the drug’s efficacy.

The radiopharmaceuticals being developed by Curie are composed of rationally designed conjugates in contrast to delicately chosen biological targets.

Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine.

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 101,700 shares of G1’s common stock to seven employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, and an aggregate of 56,400 shares of G1’s common stock to eight employees under the previously-announced G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan.

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the closing of a private placement with a single institutional investor for the purchase of 2,857,143 shares of its common stock and warrants to purchase up to an aggregate of 2,857,143 shares of common stock.

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), announced today The Lancet Respiratory Medicine (“Lancet”), an internationally trusted, peer-reviewed source of clinical, public health, and global health knowledge, published positive results from Humanigen’s LIVE-AIR Phase 3 randomized, controlled trial of lenzilumab in hospitalized COVID-19 patients.

Avivomed, Inc., a privately held, development stage, medical device company, announced the completion of a Series A Preferred Stock financing of $32 million.

TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration (“NMPA”) for marketing in mainland China (i.e., excluding Hong Kong, Macau and Taiwan regions) for the treatment of patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer and patients with metastatic colorectal cancer.